Biogen Inc (BIIB)
287.00
+1.50 +0.53%
NASDAQ
Jan 21, 16:58
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 14.23B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 28.12 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 5.396B |
| Profitability | |
| Gross Profit Margin (Quarterly) | 88.06% |
| Profit Margin (Quarterly) | 42.94% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 51.79B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 3.891 |
| PE Ratio | 10.21 |
| Price to Book Value | 3.700 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.4254 |
| Free Cash Flow (Quarterly) | 1.605B |
| Return on Equity | Upgrade |
View All BIIB News
News
-
WireHeadlineTime (ET)
-
Yahoo01/21 14:50
-
Yahoo01/20 17:32
-
MT Newswires01/17 12:05
-
Yahoo01/16 13:10
-
Yahoo01/16 05:00
-
Yahoo01/15 17:50
-
Yahoo01/15 05:39
-
Yahoo01/14 13:02
-
Yahoo01/14 09:55
-
SA Breaking News01/13 12:16
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 04/24/2020 08:00 EDT | Misc | Biogen Inc First Quarter Earnings Conference Call in 2020 |
| 04/24/2020 | Earnings | Biogen Inc First Quarter Earnings in 2020 Release |
| 01/30/2020 08:00 EST | Misc | Biogen Inc Fourth Quarter Earnings Conference Call for 2019 |
| 01/30/2020 | Earnings | Biogen Inc Fourth Quarter Earnings in 2019 Release |
| 10/22/2019 08:00 EDT | Misc | Biogen Inc Third Quarter Earnings Conference Call for 2019 |
| 10/22/2019 | Earnings | Biogen Inc Third Quarter Earnings in 2019 Release |
| 07/23/2019 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call in 2019 |
| 07/23/2019 | Earnings | Biogen Inc Second Quarter Earnings in 2019 Release |
| 06/19/2019 09:00 EDT | Misc | Biogen Inc Annual General Meeting in 2018 |
| 04/24/2019 | Earnings | Biogen Inc First Quarter Earnings Results in 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.biogen.com
- Investor Relations URL: https://www.biogen.com/en_us/investors.html
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Equity Style: Large Cap/Value
- Next Earnings Release: Jan. 30, 2020
- Last Earnings Release: Oct. 22, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 287.00 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| LMPFX | ClearBridge Aggressive Growth FI | 8.43% |
| IBB | iShares Nasdaq Biotechnology ETF | 6.13% |
| VPMCX | Vanguard PRIMECAP Inv | 3.38% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.33% |
| FBIOX | Fidelity® Select Biotechnology | 3.27% |
| VHCOX | Vanguard Capital Opportunity Inv | 2.94% |
| MOAT | VanEck Vectors Morningstar Wide Moat ETF | 2.53% |
| VPCCX | Vanguard PRIMECAP Core Inv | 1.73% |
| XBI | SPDR® S&P Biotech ETF | 1.66% |
| VGHCX | Vanguard Health Care Inv | 1.48% |
| XLV | Health Care Select Sector SPDR® ETF | 1.32% |
| VHT | Vanguard Health Care ETF | 1.22% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BIIB Tweets Stocktwits
Advertisement
